Biotrofix News - Press Releases
Biotrofix News - Press Releases BIOTROFIX - Premier Preclinical CRO - Stroke, Alzheimer's, ALS, TBI Research - Seth P. Finklestein, M.D., CEO Biotrofix News - Press Releases News from Biotrofix
Biotrofix News - Press Releases Biotrofix News - Press Releases Biotrofix News - Press Releases Biotrofix News - Press Releases Biotrofix News - Press Releases
The Company
Preclinical Drug Development
Preclinical Research Services
PK/PD Studies

Acute Stroke

Stroke Recovery

Intracerebral Hemorrhage

Alzheimer's Disease

Amyotrophic Lateral Sclerosis

Traumatic Brain Injury

Spinal Cord Injury

Muscular Dystrophy

Myocardial Infarction

Peripheral Vascular Disease


Will Travel Services
The Team
News from Biotrofix
Contact Us

Well-equipped CRO laboratory

Biotrofix News - Press Releases

Acorda Therapeutics Announces Publication of Preclinical Stroke Recovery Studies Done by Biotrofix

These studies led to a successful Phase II clinical trial in chronic stroke patients.

ARDSLEY, N.Y., May 9, 2013

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that data showing treatment with dalfampridine improved motor function in a preclinical model of post-stroke deficits have been published online ahead of print on May 7 in Stroke, a peer-reviewed journal of the American Heart Association. The data will be included in the July 2013 print edition of Stroke. Dalfampridine is the active ingredient in AMPYRA (dalfampridine) Extended Release Tablets, 10 mg.

View Full PDF Article

View Full Article in Stroke

Acorda Therapeutics Announces Clinical Phase II Data Showing that Dalfampridine Improves Walking Speed in Patients with Chronic Stroke

This clinical trial is based on Biotrofix's preclinical data.

ARDSLEY, N.Y., April 15, 2013

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that a proof-of-concept trial found dalfampridine extended release (ER) tablets, marketed as AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg, improved walking in people with post-stroke deficits. Post-stroke deficits refer to chronic neurological deficits, such as impaired walking, motor and sensory function and manual dexterity that persist in people who have had a stroke.

View Full PDF Article

Acorda Therapeutics Presents Preclinical Data Showing Dalfampridine Improves Motor Function in Chronic Stroke

First ever data to demonstrate improvement in motor function following stroke with oral drug treatment initiated several weeks after event.


Acorda Therapeutics, Inc. ACOR presented data showing that treatment with dalfampridine improved motor function in a preclinical model of stroke, with treatment initiated at least four weeks following the ischemic event. These data were presented on February 2 at the American Heart Association/American Stroke Association International Stroke Conference in New Orleans, LA. Dalfampridine, also known as 4-aminopyridine, is the active chemical ingredient in AMPYRA(R) (dalfampridine) Extended Release Tablets, 10 mg.

View Full PDF Article

Strategic Alliance Between Research Firms Will Combine Expertise in CNS and Vascular Disease Models with Translational, Multi-Modal Imaging

Ekam Imaging

Biotrofix and Ekam Imaging announce a nonclinical CRO partnership, which will provide capabilities unique in the field of neuroscience

February, 2011 - Boston, MA — Aiming to minimize risk from preclinical development, Biotrofix and Ekam Imaging announced this month they have entered into a partnering agreement together to provide synergistic capabilities to the pharmaceutical and biotechnology industries. The goal of the partnership is to deliver high-quality, accurate and translatable data that greatly assists their sponsors by allowing them to make faster and better-informed decisions.

View Full PDF Article

Preclinical Studies Show GGF2 Promotes Functional Recovery from Stroke with Treatment Initiated Up to Seven Days After Event

Biotrofix authors are co-investigators on this study.


Acorda Therapeutics, Inc, (NASDAQ: ACOR) today announced that data from preclinical studies show that Glial Growth Factor 2 (GGF2) promoted functional recovery following a permanent focal ischemic stroke. In a series of studies, GGF2 was administered starting up to seven days after the event to explore the neurorestorative properties of this novel growth factor. These studies were recently published online in Neuropharmacology, and the paper is scheduled to appear in a future print edition of the journal. An accompanying editorial discussed the need for new approaches in stroke intervention, and the potential role that GGF2 may play in improving function after stroke, pending further preclinical and clinical studies.

View Full PDF Article

Amorfix Life Sciences and Biotrofix Announce Detection of Aggregated Beta-Amyloid in CSF Using the A4 Alzheimer's Test

TORONTO, ON, October 21, 2010

Amorfix Life Sciences Ltd. (TSX:AMF) and Biotrofix, Inc. today announced that they have successfully detected the presence of the aggregated Beta-Amyloid (Abeta) peptide in the cerebral spinal fluid (CSF) from transgenic mice using the Amorfix A4 test. The results come from a collaborative study using the transgenic (Tg2576) mouse model of Alzheimer’s disease (AD). Following collection and analysis of CSF, plasma and brains from 3 month old transgenic and normal mice, they successfully detected the presence of the aggregated Abeta peptide in the CSF from the transgenic mice which correlated with the signal detected in the brains and plasma.

View Full PDF Article



Home | The Company | Preclinical Research Services | The Team | News | Publications | Contact Us | Site Map
wedgeBiotrofix, Inc.604 Webster Street, Needham, MA 02494Tel: 781-786-8890Fax: 781-465-6061

Biotrofix is a premier preclinical contract research organization specializing in animal models of CNS, cardiac and vascular disease. With years of experience, both academic, commercial, clients throughout the biotech and pharmaceutical industries, Biotrofix delivers industry-leading preclinical CRO services, including rodent models of acute stroke and stroke recovery, preclinical CRO services for Alzheimer's Disease, transgenic animal models for ALS, as well as CRO services for brain injury, preclinical CRO services for spinal cord injury and related cardiac drug discovery and development.